TY - JOUR
T1 - Prospective evaluation of patients with non-cirrhotic portal hypertension
T2 - A single centre study
AU - Mironova, Maria
AU - Gopalakrishna, Harish
AU - Viana Rodriguez, Gracia Maria
AU - Abdul Majeed, Nehna
AU - Hitawala, Asif A.
AU - Fuss, Ivan J.
AU - Bergerson, Jenna R.E.
AU - Faust, Alison J.
AU - Laurin, Jacqueline M.
AU - Norman-Wheeler, Jaha
AU - Scott, Shani
AU - Hercun, Julian
AU - Redd, Bernadette
AU - Kleiner, David E.
AU - Koh, Christopher
AU - Heller, Theo
N1 - Publisher Copyright:
© 2024 John Wiley & Sons Ltd. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
PY - 2024/6
Y1 - 2024/6
N2 - Background: Non-cirrhotic portal hypertension (NCPH) is a spectrum of liver diseases, including porto-sinusoidal vascular disorder, with portal hypertension (PH) in the absence of cirrhosis. The natural history and diagnostic approach to NCPH are not well understood. Aim: We aimed to evaluate disease progression and outcomes in NCPH. Methods: Patients with or at risk for NCPH were enrolled in a single centre prospective study; two groups were formed based on the presence of specific features of PH, such as varices, collaterals, portal hypertensive gastropathy or portal hypertensive bleeding. All participants underwent a baseline liver biopsy. Liver stiffness measurement (LSM), and imaging were repeated every 6–12 months. Results: Fifteen patients without specific features of PH (Group I), and 35 patients with specific features (Group II) were enrolled. The median follow-up time was 50 months. Group II had higher hepatic venous pressure gradients, non-invasive measures of PH and a lower platelet count (PLT) when compared to Group I. Rates of survival and decompensation were similar in both groups. Patients with PLT ≤100 K/mcL had lower survival compared to those with PLT >100 K/mcL. Patients with LSM ≥10 kPa had lower survival and survival without decompensation when compared to patients with LSM <10 kPa. Conclusions: Patients irrespective of specific features of PH had similar survival or survival without decompensation. Patients without specific features are at risk for disease progression and should be monitored closely. Thrombocytopenia and increased LSM are associated with severe forms of liver disease, which are strongly associated with outcomes.
AB - Background: Non-cirrhotic portal hypertension (NCPH) is a spectrum of liver diseases, including porto-sinusoidal vascular disorder, with portal hypertension (PH) in the absence of cirrhosis. The natural history and diagnostic approach to NCPH are not well understood. Aim: We aimed to evaluate disease progression and outcomes in NCPH. Methods: Patients with or at risk for NCPH were enrolled in a single centre prospective study; two groups were formed based on the presence of specific features of PH, such as varices, collaterals, portal hypertensive gastropathy or portal hypertensive bleeding. All participants underwent a baseline liver biopsy. Liver stiffness measurement (LSM), and imaging were repeated every 6–12 months. Results: Fifteen patients without specific features of PH (Group I), and 35 patients with specific features (Group II) were enrolled. The median follow-up time was 50 months. Group II had higher hepatic venous pressure gradients, non-invasive measures of PH and a lower platelet count (PLT) when compared to Group I. Rates of survival and decompensation were similar in both groups. Patients with PLT ≤100 K/mcL had lower survival compared to those with PLT >100 K/mcL. Patients with LSM ≥10 kPa had lower survival and survival without decompensation when compared to patients with LSM <10 kPa. Conclusions: Patients irrespective of specific features of PH had similar survival or survival without decompensation. Patients without specific features are at risk for disease progression and should be monitored closely. Thrombocytopenia and increased LSM are associated with severe forms of liver disease, which are strongly associated with outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85191021611&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85191021611&partnerID=8YFLogxK
U2 - 10.1111/apt.17987
DO - 10.1111/apt.17987
M3 - Article
C2 - 38629442
AN - SCOPUS:85191021611
SN - 0269-2813
VL - 59
SP - 1527
EP - 1538
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
IS - 12
ER -